Year: 2019
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: More than the twenty percent of ovarian cancers are hereditary, and most have BRCA mutations. The 30% of Mexican patients with the BRCA1 mutation have the BRCA1 gene exon 9-12del deletion founder mutation (BRCA1 ex9-12del). BRCA-mutated tumors are more sensitive to PARP inhibitors such as olaparib. OBJECTIVE: To show the clinical experience on the use of olaparib at Instituto Nacional de Cancerología in Mexico. METHOD: Ovarian cancer patients treated with olaparib from November 2016 to December 2018 were studied, and their characteristics, clinical response, progression-free survival (PFS) and toxicities were described. RESULTS: Nineteen patients were assessed, with BRCA1 mutation being found in 78.9%, out of which 21.1% were carriers of the ex9-12del founder mutation. The median of PFS was 12 months; for patients treated on second and third line it was > 15 months, and for those treated with a fourth and subsequent line it was 8.3 months. Patients with the founder mutation had better results. Toxicities were like those reported in previous studies. CONCLUSIONS: Olaparib offers greater PFS benefit as maintenance therapy after a first and second relapse. Patients with founder mutation have had sustained PFS.
Source: Gaceta Médica de México
Authors: Dolores Gallardo-Rincón, Gabriela Alamilla-García, Edgar Montes-Servín, Flavia Morales-Vázquez, Claudia Cano-Blanco, Jaime Coronel-Martínez, Antonio Bahena-González, Raquel Gerson-Cwilich, David Isla-Ortiz, Alfredo Toledo-Leyva, Elizabeth Montes-Servín, David Michel-Tello, Raquel Espinosa-Romero
Language: Spanish
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W2991234928
